Bispecific antibodies targeting two different immune checkpoints on T cells (anti-PD-1/CTLA-4 and anti-PD-1/TIGIT) are currently being evaluated in patients with advanced HCC in a phase II study, combining the potential benefits of two drugs in a single molecule (NCT05775159). The gene discussed is TIGIT; the disease is hepatocellular carcinoma.